RxDoctor Payments Data

Mitul Patel, MD

General Practice · East Patchogue, NYNPI 1285615120

Payments from drug & device makers

$671in general payments, 2019–2025

Across 15 payments — averaging $44.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$181
  • Bayer$100
  • Boston Scientific$98
  • Pfizer$95
  • AstraZeneca$92
  • Kerecis Limited$29
  • plus $76 from 4 others

What the payments were for

  • Food & beverage$671100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$671 in reported general payments places this provider in the 70th percentile of 5,764 general practice providers in New York.

See all general practice providers in New York

Medicare billing

Part B allowed, 2024
$643,961
Medicare patients
231
Services billed
7,659

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban158$77,374
XareltoRivaroxaban35$18,646
JanuviaSitagliptin Phosphate52$18,429
Cinacalcet Hcl15$15,338
FarxigaDapagliflozin Propanediol20$15,111
OzempicSemaglutide16$14,170
RybelsusSemaglutide13$13,210
MyrbetriqMirabegron22$9,995
EntrestoSacubitril/Valsartan13$8,967
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$8,459
Metoprolol Succinate408$4,815
Atorvastatin Calcium472$4,488
Lantus SolostarInsulin Glargine,hum.Rec.Anlog35$4,032
NamzaricMemantine Hcl/Donepezil Hcl24$3,767
Levothyroxine Sodium279$3,284

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Dilantin$95$79,425207 claims
Novo NordiskOzempic, Rybelsus$15$27,38029 claims
MerckJanuvia$17$18,42952 claims
AstraZenecaFarxiga$92$15,11120 claims
Astellas Pharma US IncMyrbetriq$22$9,99522 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 5,764 general practice providers in New York.

Other general practice in East Patchogue

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →